Papers, explained in our own words

193. Stealthy lentiviral vectors: Breaking the barriers to systemic in vivo gene delivery

Keating Al, Carlisle Rc, Mitrophanous Ka, Seymour Lw, Fisher Kd

Lentiviral vector (LVV)-mediated chimeric antigen receptor (CAR)-T cell therapy has transformed the landscape for blood cancer treatment through genetic modification of patients' T cells. Yet, the complexity of the manufacturing process makes this therapy inaccessible for many patients. Systemic intravenous delivery…

• gene therapy
• immune evasion
• immunogenicity
• lentiviral vectors
• systemic delivery

194. Phenolic Hydroxyl-Containing Lipid Nanoparticles Enable Codelivery of HPV Peptide Antigens and Manganese Adjuvant for Cancer Immunotherapy

Hou S, Zhou D, Zhang Y, Li Y, Fan D, Hu Y, Et Al.

Therapeutic peptide vaccines against HPV-associated cancers are often limited by insufficient immunogenicity and inefficient intracellular delivery. Here, we develop a phenolic hydroxyl-containing lipid nanoparticle (EMT@LNP) as a nanomedicine platform for the coordinated codelivery of HPV16 E6/E7 peptide antigens…

• HPV16 E6/E7
• cancer nanovaccine
• lipid nanoparticles
• lymph node delivery
• manganese adjuvant
• tumor immunotherapy

195. Engineered Natural Membrane Vesicle Exosomes as a Torin2 Delivery Platform for Targeted Therapy of Anaplastic Thyroid Carcinoma

Wang C, Zhang X, Qin G, Han P, Li Y, Wang X

Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy with poor prognosis due to rapid progression and resistance to conventional therapies. Integrin αvβ3 is overexpressed in ATC, making it a promising target. Torin2, a potent mTOR inhibitor, shows antitumor activity but suffers from poor solubility…

• Torin2
• anaplastic thyroid carcinoma
• exosome
• iRGD peptide
• tumor therapy

196. Ovarian Cancer Nanovaccines: Recent Strategic Advances from Antigen Selection to Carrier Design

Tang X, Huang Y, Zhang X, He C

Ovarian cancer is one of the most lethal gynecological malignancies. Its immunosuppressive tumor microenvironment and peritoneal dissemination characteristics have severely limited the efficacy of existing immunotherapies. To overcome the poor immunogenicity of tumor antigens and the need for coordinated delivery of…

• immune checkpoint inhibitors
• nanovaccine
• ovarian cancer
• tumor antigen

197. Gene therapy as an upcoming technique in the treatment of cancer: A cellular solution to a cellular problem

Bedada At, Genet S

Cancer remains a formidable global health challenge, representing the second leading cause of mortality worldwide. In 2023, there were approximately 18.5 million new cancer cases and over 10 million deaths globally, with projections estimating 30.5 million new cases and 18.6 million deaths annually by 2050. In the…

• CAR-T cells
• CRISPR-Cas9
• cancer
• carcinogenesis
• gene delivery
• gene therapy
• nanoparticles
• suicide gene therapy
• viral vectors

198. Recent Advances in Lipid Nanoparticles for Cancer Vaccines: From Antigen Delivery to Personalized Immunotherapy

Rachamala Hk, Angom Rs, Marepally S

In recent years, lipid nanoparticles (LNPs) have shown great promise as highly flexible delivery systems for cancer vaccines, which enable effective cargo delivery and allow for controlling their distribution, cell-targeting ability and immunogenicity. Innovations in ionizable lipid chemistry, biodegradable…

• cancer immunotherapy
• immune-targeted delivery
• lipid nanoparticles
• mRNA cancer vaccines
• personalized neoantigens
• tumor microenvironment

199. Bioengineered multifunctional nanomedicine for cancer theranostics: integrating targeted drug delivery, molecular imaging, and precision medicine

Dubey S, Prakash S, Deshwal Rk, Dwivedi M

Cancer remains a major global health challenge despite significant advances in diagnosis and treatment. Conventional therapies, including chemotherapy, radiotherapy, and surgery, are frequently constrained by non-specific drug distribution, systemic toxicity, multidrug resistance (MDR), and limitations in early tumor…

• cancer imaging
• drug delivery systems
• nanomedicine
• nanoparticles
• targeted cancer therapy

200. Drug Delivery Systems for Breast Cancer Treatment: From Design Principles to Clinical Translation

Sescu Va, Condriuc Ips, Spridon Lg, Cadinoiu An, Miron L, Atanase Li, Et Al.

Breast cancer is the most frequently diagnosed malignancy worldwide and remains a major cause of cancer-related mortality among women. Despite advances in screening, molecular classification, and systemic therapies, treatment of advanced and metastatic disease remains challenging because of tumor heterogeneity…

• breast cancer
• clinical translation
• drug delivery systems
• nanocarriers
• nanomedicine
• targeted drug delivery

201. Advances and Translational Challenges in mRNA–Lipid Nanoparticle Vaccines Against Helicobacter pylori : From Rational Antigen Design to Mucosal Immunity

Zhao Y, Cheng H, Zhou S, He L, Xiu C, Huang B, Et Al.

Helicobacter pylori chronically infects more than half of the global population and is the sole bacterium classified as a Group 1 carcinogen by the International Agency for Research on Cancer. Despite decades of effort, no prophylactic H. pylori vaccine has reached the market, largely because conventional subunit and…

202. Exosome-Inspired Proteolipid Nanoparticles Enable Safe, Extrahepatic RNAi-Chemo Therapy Through Cholesterol-Free, Tumor-Preferential Delivery

Ren Y, Wang Q, Li P, Zhang Z, Wei G, Tan Y, Et Al.

Lipid nanoparticle (LNP)-enabled genetic medicines are reshaping cancer therapy yet remain constrained by liver-biased tropism, dose-limiting toxicities, and limited efficacy in refractory solid tumors such as pancreatic ductal adenocarcinoma (PDAC). Here, exosome-inspired proteolipid nanoparticles (Em-pLNPs) are…

• exosome mimetics
• extrahepatic delivery
• gene therapies
• lipid nanoparticles
• pancreatic ductal adenocarcinoma

203. Comparative Analysis of Poly(Ethylene Glycol) (PEG) and Poly(2-Ethyl-2-Oxazoline) (PEtOx) for Organic Solvent-Free Lipid Nanoparticle Formulations

Streiber M, Holick Ct, Gath L, Tsarenko E, Bachmann V, Litsiou S, Et Al.

Efficient, biocompatible, and flexible application of CRISPR-Cas9 remains a major challenge in gene therapy. This study addresses a novel formulation method, focusing on organic solvent-free lipid nanoparticles for the efficient delivery of CRISPR-Cas9 components. Therefore, novel stealth lipids comprising the lipid…

• CRISPR‐Cas9
• lipid nanoparticles
• liquid chromatography
• mRNA delivery
• organic solvent‐free

204. Gene-Editing in Respiratory Disease: From Pre-Clinical Human Models to Future Therapeutics

Duffy A, Schweikert A, Tan Sy, Murphy C, Dowling Cm, Hurley K, Et Al.

Chronic lung diseases arise from complex interactions between environmental exposures and host genetic factors. However, these interactions are not fully understood, and despite decades of study, effective curative therapies remain unavailable for many patients. Recent breakthroughs in therapeutic gene-editing have…

• CRISPR
• disease modelling
• gene-editing
• gene-therapies
• genetic lung disease
• iPSCs

205. Lipid Nanoparticle Delivery of CAR276 mRNA Enables Antigen-Specific Cytotoxicity in T Cells Against Glioblastoma Cells

Zahedipour F, Sadeghianfard S, Wisser S, Dinarvand M, Steiner D, Ramesh A, Et Al.

Background/Objectives: Glioblastoma multiforme (GBM) remains the most aggressive and treatment-refractory primary brain tumor, with current therapeutic modalities providing minimal survival improvement. Chimeric antigen receptor (CAR)-based immunotherapies succeeded in hematologic malignancies but are constrained in…

• CAR-T cell engineering
• CD276 (B7-H3)
• glioblastoma
• lipid nanoparticles
• mRNA delivery

206. Biomimetic Nanoparticles With Overexpressed Adhesion Proteins for Targeted Delivery of Gambogic Acid in Hepatocellular Carcinoma

Zhang Y, Yang M, Wu Y, Zhang Y, Xu J, Zheng J, Et Al.

Cancer cell membrane coating offers a promising strategy for targeted drug delivery, yet its homotypic targeting mechanism and optimization remain insufficiently understood. This study identifies epithelial cell adhesion molecule (EpCAM), rather than Galectin-3, as the pivotal mediator of homologous uptake in…

• Biomimetic nanoparticles
• Cell membrane coating
• Clathrin‐mediated endocytosis
• EpCAM overexpression
• Homologous tumor targeting

207. Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer

Anwer K, Sood S, Sparks J, Faller Dv, Limon A, Lindborg Sr

Interleukin-12 (IL-12) is a potent immunostimulatory cytokine with well-established antitumor activity, but systemic recombinant IL-12 administration has been constrained by inflammatory toxicity, high circulating cytokine peaks, and insufficient tumor-local exposure. IMNN-001 is a non-viral IL-12 gene therapy…

• IL-12
• immunotherapy
• non-viral gene delivery
• ovarian cancer
• plasmid DNA

208. Topical Vitamin D Analogs Beyond Psoriasis: Pharmacological Mechanisms, Cutaneous Drug Delivery, and Clinical Evidence

Laçej D, Pietrella A, Zoratto N, Lombardi M, Di Meo C, Matricardi P

Topical vitamin D analogs are well-established therapies for psoriasis, but their broader dermatologic potential increasingly depends not only on their biological activity but also on the ability of topical formulations to achieve effective and localized cutaneous delivery. This narrative review critically examines…

• calcipotriol
• calcitriol
• cutaneous delivery
• skin targeting
• tacalcitol
• topical drug delivery
• topical formulations
• vitamin D analogs

209. Synthetic Poly(2-Oxazoline) Chimera 'Lipo-Polymers' as Replacements for Key Lipids in Lipid Nanoparticles

Ramsey Jd, Haney M, Zhao Y, Hutsell H, Kabanov A

Lipid nanoparticles (LNPs) rely on specialized lipid components, many of which are proprietary and difficult to access or modify. Here, we introduce a polymer-based alternative to key LNP constituents through the development of chimera poly(2-oxazoline) (POx) synthetic lipid polymers (SLPs) and synthetic lipid…

210. Self-Catalyzed Transesterification Transforms Ionizable Amphiphilic Janus Dendrimers into Multicomponent Vectors and Generates Complex Design Strategies for mRNA Delivery

Lu J, Atochina-Vasserman En, Sahoo D, Maurya Ds, Tiwary A, Arshad M, Et Al.

Genetic nanomedicine delivers nucleic acids by viral and synthetic vectors to produce drugs directly in the body's own cells. Each approach presents relative advantages, but synthetic vectors are distinguished by their effectively unlimited synthetic capabilities. The leading synthetic vectors are the four-component…

211. Gene Therapy for Osteoarthritis: Viral and Non-Viral Delivery Strategies

Zhang M, Mohess J, Cheung J, Du Q, Qiu J, Wang J

Osteoarthritis (OA) is the most prevalent joint disease, which is pathologically characterized by articular cartilage degradation, chronic synovial inflammation, subchondral bone remodeling, and osteophyte formation. Patients with OA suffer from joint pain, deformity, and functional impairment. Current therapies…

• clinical trials
• gene therapy
• non-viral delivery
• osteoarthritis
• viral vectors

212. Uncovering the lymphatic uptake, pharmacokinetics, and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection

Li P, Abdallah M, Yao Y, Mugan Rs, Payne Tj, Fabb Sa, Et Al.

Lipid nanoparticle (LNP) formulations have enabled the in vivo delivery of messenger ribonucleic acid (mRNA) vaccines and therapeutics yet the delivery of RNA remains relatively inefficient. In order to improve LNP design there is a need to better understand how current mRNA-LNP formulations are trafficked and…

• Biodistribution
• Intravenous injection
• Ionizable lipid
• Lipid nanoparticle
• Lymphatics
• Pharmacokinetics
• Subcutaneous injection
• mRNA

213. Self-Monitoring Theranostic Nanomaterials for Biomedical Imaging and Cancer Therapy: Real-Time Visualization of Biodistribution, Payload Release, and Therapeutic Response

Choi C, Seo D, Park J, Yu D, Song S, Yu S, Et Al.

Theranostic nanomedicines integrate therapeutic delivery with diagnostic imaging, but many conventional platforms primarily visualize nanocarrier localization and provide limited information on whether the therapeutic payload has been released, the intended treatment mechanism has been activated, or a meaningful…

• biomedical imaging
• cancer therapy
• payload release
• self-monitoring nanomaterials
• theranostic nanomedicine
• therapeutic response

214. Disulfide bond-modified ionizable lipids for co-delivery of siRNA and carbon dots in the treatment of acute liver injury

Chu R, Shen Z, Pan T, Gao Q, Wang Z, He J

Acute liver injury (ALI) is a severe clinical condition characterized by excessive oxidative stress and inflammatory responses, for which effective targeted therapeutic strategies remain limited. In this study, a redox-responsive ionizable lipid (Lipid S) was designed by incorporating a disulfide bond into its…

• Acute liver injury
• Carbon dots
• Disulfide bond
• Interleukin-11 receptor alpha-1
• Ionizablelipids

215. AI-Driven miRNA Target Identification Combined with Nanocarrier-Based Therapy Enhances Amastigote Clearance in Canine Visceral Leishmaniasis: An Integrated In Silico and Ex Vivo Study

Spyridonis A, Lefkaditis M, Pappas I, Lialiaris T, Perakis P

Study rationale and knowledge gap: Canine visceral leishmaniasis is a major zoonotic disease in which intracellular Leishmania infantum persists within macrophages, while treatment limitations and emerging resistance highlight the need for improved therapeutic strategies. MicroRNA-mediated regulation of host immune…

216. Enhancing mRNA-lipid nanoparticle vaccine-induced T cell responses by simple supplementation with class B CpG oligodeoxynucleotides

Hirata H, Abe Y, Itoh Y, Hirai T, Yoshioka Y

mRNA-lipid nanoparticle (LNP) vaccines can elicit robust T cell responses; however, these responses remain insufficient, particularly in the context of cancer vaccine therapy. Although several types of adjuvants reportedly enhance T cell responses induced by mRNA-LNP vaccines, few comprehensive side-by-side…

• Adjuvant
• Adverse reactions
• Cancer vaccine
• Class B CpG ODN
• Particle characteristics
• mRNA-LNP vaccine